VivoSeq
Other

Arterial Occlusive Disease

10

Pipeline Programs↗

1

Active Trials↗

8

Companies Involved↗

Arterial Occlusive Disease is an early-stage landscape with 10 programs across 8 companies. The most active players are Boehringer Ingelheim, Takeda, Viatris Specialty LLC. 3 therapies are approved with 1 more in late-stage development.

Intelligence

Pipeline Metrics

Competitive Density

37/100

Pipeline Velocity

6/100

Mech. Concentration

14/100

Completion Rate

100/100

Attrition Rate

0/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

Boehringer Ingelheim logo

Boehringer Ingelheim

1 program

Phase 2Takeda logo

Takeda

1 program

Phase 3V

Viatris Specialty LLC

2 programs

ApprovedSanofi logo

Sanofi

1 program

ApprovedAstraZeneca logo

AstraZeneca

1 program

PreclinicalP

Pfizer's Upjohn has merged with Mylan to form Viatris Inc.

1 program

Preclinical

Pipeline

Programs by Phase

Analysis

Modality Breakdown

91%

Small molecule

10 of 11 classified programs — the dominant modality here.

9%ALL OTHERSMonoclonal antibody19%

Small molecule leads; the ring shows all 11 classified programs, each share of the total. Modality classified for 100% of 11 pipeline programs.

Analysis

Trial Status

6

clinical trials

Completed3 · 50%
Unknown status2 · 33%
Recruiting1 · 17%

Clinical Trials

Trial Activity

6 trials

Safety of Antithrombotic Heparin Proteoglycan Mimetic APAC in Peripheral Arterial Occlusive Disease and Chronic Limb-threatening Ischemia
Recruiting·—·Phase 2·NCT07352800·42 enrolled
Effect of NCX4016 on Walking Distance in Patients With Peripheral Arterial Occlusive Disease (PAOD)
Completed·NNicOx Research Institute S.r.l.·Phase 2·NCT01256775·442 enrolled
Alprostadil in Peripheral Arterial Occlusive Disease (PAOD) Stage IV
Completed·UCB logoUCB·Phase 4·NCT00596752·840 enrolled
Actovegin 12-Week Treatment Given First Intravenously and Subsequently Orally in Participants With Peripheral Arterial Occlusive Disease Fontaine Stage IIB
Completed·Takeda logoTakeda·Phase 3·NCT03469349·366 enrolled
Magnesium Oral Supplementation to Reduce Pain Inpatients With Severe Peripheral Arterial Occlusive Disease
Unknown status·AAzienda Socio Sanitaria Territoriale degli Spedali Civili di Brescia·N/A·NCT02455726·150 enrolled
Prostaglandin E1 (Liprostin) Treatment With Lower Limb Angioplasty for Peripheral Arterial Occlusive Disease
Unknown status·EEndovasc·Phase 2·NCT00053716·12 enrolled

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)